会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • Self-elevating platform scaffolding
    • 自升式平台脚手架
    • US20070193831A1
    • 2007-08-23
    • US11356535
    • 2006-02-17
    • Michael Vance
    • Michael Vance
    • E04G3/28
    • E04G1/20B66B9/022B66F7/12
    • The self-elevating platform scaffolding includes a horizontal work platform suspended from a vertical mast tower and a unique lift mechanism mounted to the work platform, which raises and lowers the platform along the length of the tower. The lift mechanism uses a pinion wheel that directly engages a mast tower to raise and lower the work platform along the mast towers. The pinion wheel has a plurality of radially spaced cogs that seat within crescent shaped openings in the mast tower. The lift mechanism is mounted to the work platform adjacent the mast tower such that rotation of the pinion wheel causes the wheel to “walk” up and down the mast tower to raise and lower the platform. The geometric configuration of the pinion wheel is designed so that at least two of the cogs are always in contact with the mast tower. As the pinion wheel turns, each successive cog seats within an adjacent crescent slot in the mast tower with its contact edge bearing against the bottom edge of tower opening.
    • 自升式平台脚手架包括从垂直桅杆塔悬挂的水平工作平台和安装到工作平台上的独特升降机构,其沿着塔的长度升高和降低平台。 升降机构使用直接接合桅杆塔的小齿轮,以沿着桅杆塔升起和降下工作平台。 小齿轮具有多个径向隔开的齿,其位于桅杆塔架中的月牙形开口内。 升降机构安装在靠近桅杆塔架的工作平台上,使得小齿轮的旋转导致车轮上下桅杆塔升降平台。 小齿轮的几何构型被设计成使得至少两个齿轮总是与桅杆塔接触。 当小齿轮转动时,每个连续的齿轮座位于桅杆塔架中邻近的新月形槽内,其接触边缘抵靠塔架开口的底部边缘。
    • 7. 发明授权
    • Oxazole PPAR antagonist
    • 恶唑PPAR拮抗剂
    • US06506781B1
    • 2003-01-14
    • US10070474
    • 2002-03-07
    • Jeffrey Edmond CobbMillard Hurst Lambert, IIIMichael Vance MilburnBarry George Shearer
    • Jeffrey Edmond CobbMillard Hurst Lambert, IIIMichael Vance MilburnBarry George Shearer
    • A61K314245
    • C07D413/12C07D263/32C07D417/12
    • A method is disclosed for rational design of a PPAR, FXR, LXR-alpha, or LXR-beta antagonist comprising chemical modification of a PPAR, FXR, LXR-alpha, or LXR-beta agonist to: a) prevent formation of a hydrogen bond between the agonist and tyrosine or histidine, or tryptophan involved in receptor activation; and/or b) displace the tyrosine or histidine, or tryptophan involved in receptor activation from its agonist bound position. Preferably, little or no additional changes are made in the structure of the agonist so that the resulting antagonist is a close structural analogue of the agonist. Specific examples of PPAR gamma antagonists designed and prepared using the method of this invention are compounds of Formula (I) or (II), or pharmaceutically acceptable salts or solvates thereof, where in Formula (I) X is O, S, or NH; and R is methyl, ethyl, n-propyl, i-propyl, cyclopropyl, n-butyl, phenyl, or —CH2OCH3 and wherein in Formula (II) X is C or N; and R is methyl, ethyl, n-propyl, i-propyl, —CH2OCH3, or —CO2CH3.
    • 公开了用于合理设计PPAR,FXR,LXR-α或LXR-β拮抗剂的方法,其包括PPAR,FXR,LXR-α或LXR-β激动剂的化学修饰以:a)防止形成氢键 激动剂与酪氨酸或组氨酸或参与受体活化的色氨酸之间; 和/或b)从其激动剂结合位置置换参与受体活化的酪氨酸或组氨酸或色氨酸。 优选地,在激动剂的结构中进行很少或没有额外的改变,使得所得拮抗剂是激动剂的紧密结构类似物。 使用本发明方法设计和制备的PPARγ拮抗剂的具体实例是式(I)或(II)化合物或其药学上可接受的盐或溶剂合物,其中在式(I)中X是O,S或NH; 并且R是甲基,乙基,正丙基,异丙基,环丙基,正丁基,苯基或-CH 2 OCH 3,并且其中在式(II)中,X是C或N; R为甲基,乙基,正丙基,异丙基,-CH 2 OCH 3或-CO 2 CH 3。